BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 23 filers reported holding BAXTER INTL INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $42,756 | -47.4% | 1,132,900 | -36.5% | 0.07% | -37.6% |
Q2 2023 | $81,274 | -45.5% | 1,783,900 | -51.5% | 0.12% | -40.9% |
Q1 2023 | $149,050 | +79.4% | 3,674,800 | +125.4% | 0.20% | +73.7% |
Q4 2022 | $83,096 | -99.4% | 1,630,300 | +549.0% | 0.11% | +500.0% |
Q3 2022 | $13,530,000 | +192.5% | 251,200 | +248.9% | 0.02% | +280.0% |
Q2 2022 | $4,625,000 | -95.8% | 72,000 | -95.0% | 0.01% | -96.2% |
Q1 2022 | $111,192,000 | +136.0% | 1,434,000 | +161.2% | 0.13% | +120.3% |
Q4 2021 | $47,123,000 | -57.8% | 548,968 | -60.5% | 0.06% | -59.0% |
Q3 2021 | $111,669,000 | +83.7% | 1,388,400 | +83.8% | 0.14% | +89.5% |
Q2 2021 | $60,794,000 | +119.8% | 755,200 | +130.2% | 0.08% | +123.5% |
Q1 2021 | $27,664,000 | -57.6% | 328,000 | -59.7% | 0.03% | -52.1% |
Q4 2020 | $65,316,000 | +899.0% | 814,009 | +901.2% | 0.07% | +914.3% |
Q3 2020 | $6,538,000 | -84.8% | 81,300 | -83.7% | 0.01% | -81.1% |
Q2 2020 | $43,007,000 | +924.5% | 499,500 | +866.1% | 0.04% | +825.0% |
Q1 2020 | $4,198,000 | -95.6% | 51,702 | -96.4% | 0.00% | -92.3% |
Q2 2018 | $95,958,000 | +31.4% | 1,433,345 | +27.7% | 0.05% | -35.0% |
Q1 2018 | $73,023,000 | -24.0% | 1,122,745 | -24.5% | 0.08% | -24.5% |
Q4 2017 | $96,114,000 | +227.2% | 1,486,913 | +217.6% | 0.11% | +202.9% |
Q3 2017 | $29,374,000 | -75.5% | 468,113 | -76.3% | 0.04% | -77.1% |
Q2 2017 | $119,773,000 | +21.7% | 1,978,413 | +4.3% | 0.15% | +11.7% |
Q1 2017 | $98,384,000 | +3361.8% | 1,897,115 | +2859.6% | 0.14% | +3325.0% |
Q4 2016 | $2,842,000 | -62.2% | 64,100 | -59.4% | 0.00% | -69.2% |
Q3 2016 | $7,521,000 | -71.5% | 158,000 | -72.9% | 0.01% | -74.0% |
Q2 2016 | $26,372,000 | +24.2% | 583,200 | +12.8% | 0.05% | +25.0% |
Q1 2016 | $21,240,000 | +13.1% | 517,032 | +5.1% | 0.04% | -2.4% |
Q4 2015 | $18,775,000 | -21.5% | 492,132 | -32.4% | 0.04% | -28.1% |
Q3 2015 | $23,922,000 | -82.1% | 728,232 | -62.6% | 0.06% | -79.9% |
Q1 2015 | $133,335,000 | +933.7% | 1,946,500 | +1006.0% | 0.28% | +816.1% |
Q4 2014 | $12,899,000 | -72.3% | 176,000 | -72.9% | 0.03% | -75.8% |
Q3 2014 | $46,629,000 | -45.6% | 649,700 | -45.2% | 0.13% | -36.0% |
Q2 2014 | $85,647,000 | +43.3% | 1,184,600 | +45.8% | 0.20% | +39.9% |
Q1 2014 | $59,776,000 | -9.7% | 812,400 | -14.6% | 0.14% | -9.5% |
Q4 2013 | $66,184,000 | -44.4% | 951,600 | -47.5% | 0.16% | -45.3% |
Q3 2013 | $119,096,000 | +10.5% | 1,813,000 | +16.5% | 0.29% | +2.1% |
Q2 2013 | $107,798,000 | – | 1,556,200 | – | 0.28% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
13D Management LLC | 194,807 | $11,794,000 | 4.18% |
Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |